DGAP-News: WILEX AG: WILEX Inc. and IBL-America sign non-exclusive marketing and distribution agreement for USA
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: WILEX Inc. and IBL-America sign non-exclusive marketing and
distribution agreement for USA
31.01.2013 / 07:07
---------------------------------------------------------------------
PRESS RELEASE
WILEX Inc. and IBL-America sign non-exclusive marketing and distribution
agreement for USA
Munich, Germany / Minneapolis, USA, 31 January 2013 WILEX AG (ISIN
DE0006614720/ WL6 / FSE) today announced that its US subsidiary WILEX Inc.,
Cambridge, MA, USA, entered into a non-exclusive marketing and distribution
agreement with Immuno-Biological Laboratories Inc., Minneapolis, MN, USA,
(IBL-America) for the commercialization of the complete diagnostic
portfolio in the USA. IBL-America is a distributor of high quality
diagnostic assays in various areas including autoimmunity, endocrinology,
infectious disease, oncology and neuroscience and offers technical
laboratory services as well. Financial terms were not disclosed.
WILEX Inc. is a specialist in serum based oncoprotein diagnostics and
offers tests for In Vitro Diagnostic (IVD) and Research Use Only (RUO)
under the brand Oncogene Science. WILEX Inc. provides the only FDA-cleared
through 510(k) IVD ELISA test for the measurement of serum HER-2/neu in the
management and monitoring of women with metastatic breast cancer. This
microtiter based test enables laboratories to measure the level of
HER-2/neu in serum in a cost-efficient and validated manner. This test is
reimbursed by insurance companies and has a unique CPT code 83950. In
addition, WILEX Inc. also offers a CAIX IHC Class 1 IVD test for the
pathology market and CAIX RUO ELISA for measuring this hypoxia biomarker in
serum or plasma. CAIX is highly overexpressed in renal cell cancer and
several other major cancers. The portfolio also includes RUO ELISA kits for
the detection of oncoproteins in serum including targets like uPA, PAI-1,
TIMP-1 and EGFR.
The 2011 signed exclusive distribution contract between WILEX Inc. and
American Laboratory Products Company Inc., Salem, NH, USA, (ALPCO
Diagnostics) for the co-marketing and distribution of the Serum HER-2/neu
ELISA test in USA and Canada was terminated recently by mutual agreement.
Professor Olaf G. Wilhelm, CEO of WILEX Inc. and WILEX AG, commented: 'As
the American market is quite fragmented we decided to terminate our
exclusive distribution agreement and to open up the business for
IBL-America. With more than 16 years of hands-on experience and existing
sales in oncology, we believe that IBL-America is an ideal partner to
successfully market and distribute our portfolio of biomarker tests.'
Mark A. Kowal, President and CEO of IBL-America said: 'We believe the
Oncogene Science diagnostic tests are an attractive addition to our
existing product portfolio. Especially the Serum HER-2/neu ELISA offers an
important diagnostic application for improving breast cancer patient care.
We already have a well-established distribution network to gynecologists
and labs for our HE4 assay to monitor recurrence or progressive disease in
patients with epithelial ovarian cancer and will use this distribution
channel to promote the Oncogene Serum HER-2/neu ELISA as well.'
About IBL-America
IBL-America is a privately owned US corporation located in Minneapolis, MN,
and since 1997 has been an established provider of in-vitro diagnostic
assays to major US laboratories and hospitals. With annual sales of $4MM+
IBL-America continues to provide the diagnostic community with the products
and technical service required to meet today's high quality standards and
regulations. Additionally IBL-America supplies research assays as well as
antibodies and proteins to thousands of laboratories across North and South
America. Through their sister company, KMI Diagnostics, Inc., IBL-America
can also provide testing services for endocrinology and research projects.
More information is available at www.ibl-america.com and
www.kmidiagnostics.com.
About WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG, Munich, Germany.
The team has experience for many years in developing and manufacturing
biomarker tests for oncology, which are marketed under the brand name
Oncogene Science. The product portfolio includes Enzyme-linked
ImmunoSorbent Assays (ELISA) and immunohistochemical (IHC) assays. With the
aim of supporting treatment regimens for cancer patients worldwide WILEX
Inc. offers biomarker tests for measuring oncogenes, growth factor
receptors (HER-2/neu, EGFr), proteases and protease inhibitors (uPA, PAI-1,
TIMP-1), as well as markers of hypoxia (CAIX). In addition to the new CAIX
IHC which is a class 1 IVD test, WILEX Inc. provides the only FDA-cleared
and CE-marked IVD ELISA that measures the serum HER-2/neu level for the
management and monitoring of patient care for women with metastatic breast
cancer. WILEX Inc. is based in Cambridge, MA, USA and also provides GMP and
ISO certified manufacturing services. More information is available on
www.oncogene.com.
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer based on antibodies and small molecules. Beside the
manufacturing and marketing of the biomarker tests from WILEX Inc. the
subsidiary Heidelberg Pharma GmbH offers preclinical contract research
services and an antibody drug conjugate (ADC) technology platform. The
business model comprises research and product development as well as the
commercialisation of its activities. Our customers and partners include
leading international pharmaceutical companies. WILEX AG is listed at the
Frankfurt Stock Exchange. ISIN DE0006614720 / WKN 661472 / Symbol WL6. More
information is available on http://www.wilex.com.
Contact
WILEX AG Immuno-Biological Laboratories Inc.This communication contains certain forward-looking statements relating to
Corporate Communications
Katja Arnold (CIRO) Mark A. Kowal
Grillparzerstr. 10 President / CEO
81675 Munich, Germany 8201 Central Ave NE, Suite P
Tel.: +49 (0)89-41 31 38-126 Minneapolis, Minnesota 55432
Fax: +49 (0)89-41 31 38-99 Tel: 1-763-780-2955
Email: investors(at)wilex.com Fax: 1-763-780-2988
Email: mkowal(at)ibl-america.com
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
31.01.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
200228 31.01.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 31.01.2013 - 07:07 Uhr
Sprache: Deutsch
News-ID 224733
Anzahl Zeichen: 5581
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 292 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG: WILEX Inc. and IBL-America sign non-exclusive marketing and distribution agreement for USA"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
